Navigation Links
Study indicates nanoparticles could help pain-relieving osteoarthritis drugs last longer
Date:10/26/2011

Arlington, Va. A novel study demonstrates that using nanoparticles to deliver osteoarthritis drugs to the knee joint could help increase the retention of the drug in the knee cavity, and therefore reduce the frequency of injections patients must receive. This research is being presented Oct. 23 27 at the 2011 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in Washington, D.C.

Osteoarthritis affects 30 million Americans and is the most common joint disorder. It is projected to affect more than 20 percent of the U.S. population by 2025. Aging, obesity and joint injury can lead to osteoarthritis, which is characterized by progressive erosion of articular cartilage (cartilage that covers the bones). The disease can occur in all joints, most often the knees, hips, hands and spine, and currently there are no pharmacological treatments that halt the disease progression. For large joints, a drug could be injected into the joint to help limit potential side effects, like pain. A significant challenge in treating osteoarthritis this way is the short duration the medicine stays in the affected joint after injection.

Lead researcher Michael Morgen, Ph.D., and his colleagues from Bend Research and Pfizer propose to address this challenge with injectable nanoparticles that help retain osteoarthritis drugs in the knee joint. Test results show that 70 percent of the drug nanoparticles remain in the knee cavity after one week. In contrast, for most current formulations, the drug disperses within one to two days.

In this new process, positively charged nanoparticles carrying a drug attach to the negatively charged, naturally occurring molecules in the knee to form a gel. This gel acts as a depot that slows drug escape from the knee cavity.

"Current delivery methods do not maintain the drug in the knee for very long, which limits the effectiveness of therapeutic agents," said Dr. Morgen. "We hope that this type of sustained release technology, when used with current or new osteoarthritis drugs, will allow patients to be effectively treated with drug injections every three months instead of once a week."


'/>"/>

Contact: Stacey May
MayS@aaps.org
703-248-4740
American Association of Pharmaceutical Scientists
Source:Eurekalert

Related medicine news :

1. Study shows why underrepresented men should be included in binge eating research
2. Some Asthma Drugs Raise Risk of Complications, Especially in Kids: Study
3. Sleepy Teens More Prone to Weight Gain: Study
4. Scott & White Healthcare and American Cancer Society enter into partnership for prevention study
5. IADR/AADR publish study on dental caries vaccine
6. Penn study explains paradox of insulin resistance genetics
7. Wayne State University study of heroin users to examine links between stress, drug use
8. Study Casts Doubt on Hot Dogs Link to Colon Cancer
9. Study: Obesity limits effectiveness of flu vaccines
10. Soft Drinks Linked to Violent Tendencies in Teens: Study
11. Yoga, Stretching Classes Outdo Self-Care for Back Pain: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... In honor of ... and corporate training, and the National Military Family Association, a nonprofit that works ... the second full-tuition scholarship recipient of 2016. , “Being awarded this scholarship ...
(Date:5/5/2016)... ... , ... TransWipe Volume 3 is a set of 30 professional transition animations ... between two video clips to instantly add a unique transition to any Final Cut ... and orientation options. TransWipe Volume 3 is a Final Cut Pro X exclusive plugin. ...
(Date:5/5/2016)... ... May 05, 2016 , ... The U.S. Food ... requiring e-cigarette manufacturers to submit their products through an arduous federal approval process. ... products that entered the market since February 15, 2007. That would essentially ban ...
(Date:5/5/2016)... SAN FRANCISCO (PRWEB) , ... May 05, 2016 ... ... in the Unites States to promise successful results with IVF and with egg ... Designed to deliver the most patient-centric and highest quality fertility care, Spring Fertility ...
(Date:5/5/2016)... Bremerton, WA (PRWEB) , ... May 05, 2016 , ... ... program serving the families of Bremerton, Port Orchard and communities west of Seattle. The ... Lowery, a 12 year local girl who died suddenly due to complications from the ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... 4, 2016 Global Insulin ... profiling 09 key companies and supported with 272 ... in-depth study on the current state of the ... the industry including definitions, classifications, applications and industry ... provided for the international market including development history, ...
(Date:5/3/2016)... from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities and increase market presence. ... ... ... ... Sino-German High-Tech ...
(Date:5/3/2016)... 2016   BIOTRONIK , a leader in ... and Drug Administration (FDA) approval of Iperia ProMRI ... failure patients with access to diagnostic magnetic resonance ... monitoring with daily automatic transmission and closed loop ... response to physiological demands. ...
Breaking Medicine Technology: